Article
Pharmacology & Pharmacy
Ji-Hea Kim, Seung-Jin Lee, Ka-Won Kang, Byung-Hyun Lee, Yong Park, Byung-Soo Kim
Summary: The study shows that inhibiting the CXCR2-mTOR-c-Myc cascade has significant therapeutic effects in overcoming both TKI-sensitive and TKI-insensitive CML. The CXCR2 antagonist SB225002 demonstrates promising results in treating TKI-resistant CML patients.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Francesca Ruzzi, Arianna Palladini, Stine Clemmensen, Anette Strobaek, Nicolaas Buijs, Tanja Domeyer, Jerzy Dorosz, Vladislav Soroka, Dagmara Grzadziela, Christina Jo Rasmussen, Ida Busch Nielsen, Max Soegaard, Maria Sofia Semprini, Laura Scalambra, Stefania Angelicola, Lorena Landuzzi, Pier-Luigi Lollini, Mette Thorn
Summary: The ES2B-C001 vaccine shows promising preclinical activity in the treatment of HER-2(+) breast cancer, effectively inhibiting tumor growth and metastasis. Vaccination induces strong antibody responses and does not cause cytokine storms. These results provide a basis for further human clinical studies.
Review
Pharmacology & Pharmacy
Gustavo P. Amarante-Mendes, Aamir Rana, Tarcila Santos Datoguia, Nelson Hamerschlak, Gabriela Brumatti
Summary: The constitutively active BCR-ABL1 tyrosine kinase plays a role in leukemia and initiates a complex signaling transduction cascade. Tyrosine kinase inhibitors have revolutionized the treatment of CML, but complete cure is not achieved. Other mechanisms exist in the later stages of the disease.
Review
Pharmacology & Pharmacy
Wenjing Xiao, Qiaodan Zhou, Xudong Wen, Rui Wang, Ruijie Liu, Tingting Wang, Jianyou Shi, Yonghe Hu, Jun Hou
Summary: Cancer treatment remains a significant challenge globally, with epigenetic modification being identified as a key target for drug development. By adding chemical groups to the DNA backbone and modifying chromatin architecture through various enzymes, epigenetic drugs have shown promising effects in both preclinical and clinical studies. Developing small-molecule inhibitors targeting epigenetic modified enzymes has become a focus for future cancer therapy research.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Huafeng Jiang, Senjun Zhou, Gang Li
Summary: Colorectal cancer (CRC) is a common and lethal type of cancer, and early diagnosis and treatment can significantly improve survival chances. Recent advancements in molecular biology have led to the discovery of novel biomarkers for early diagnosis, including the gut microbiota as a potential biomarker for CRC screening and treatment. Treatment options for CRC include surgical resection, chemotherapy, immunotherapy, and targeted therapies such as tyrosine kinase inhibitors (TKIs). However, there is a knowledge gap when it comes to bringing tailored medicines into clinical practice.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Weikang Xu, Xinyu Lu, Jing Liu, Qianhui Chen, Xuan Huang, Kuiyuan Huang, Hongyan Liu, Wei Zhu, Xiaoyong Zhang
Summary: PAFAH1B3 expression is significantly increased in HCC patients, and high expression is associated with poorer overall survival and disease-free survival. PAFAH1B3 may be involved in HCC through cell cycle, cell metabolism, spliceosome, and RNA transport. Inhibiting PAFAH1B3 impairs HCC cell proliferation, invasion, and migration, while downregulating glycolysis and lipid synthesis pathways.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Kunyu Shi, Guan Wang, Junping Pei, Jifa Zhang, Jiaxing Wang, Liang Ouyang, Yuxi Wang, Weimin Li
Summary: This review discusses the molecular mechanisms of resistance to third-generation EGFR inhibitors and reviews recent strategies for overcoming resistance, new challenges, and future development directions.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Review
Oncology
Prachi Mishra, Dipranjan Laha, Robert Grant, Naris Nilubol
Summary: This article reviews current treatment practices for thyroid cancer and emphasizes on novel targeted molecular therapy. With rapidly expanding knowledge of the molecular biology and increased availability of genetic testing, exciting paradigm shifts in treatment strategies have been observed. Targeted therapies and personalized treatments have become a trend with the development of new treatment strategies, accelerating the advancement of treatments for thyroid cancer.
Article
Oncology
Zhigui Li, Hongzhao Yang, Jianbo Liu, Li Li, Xiaodong Wang
Summary: A study found that expression levels of TOMM34 gene and protein are elevated in colon cancer. High TOMM34 expression is associated with low levels of immune cell infiltration and poor prognosis. These findings suggest that TOMM34 may serve as a potential biomarker for diagnosis and prognosis prediction of colon cancer.
FRONTIERS IN ONCOLOGY
(2023)
Review
Endocrinology & Metabolism
Ivana Puliafito, Francesca Esposito, Angela Prestifilippo, Stefania Marchisotta, Dorotea Sciacca, Maria Paola Vitale, Dario Giuffrida
Summary: Thyroid cancer is the most common endocrine malignancy, and its subtypes have been studied for novel therapeutic options. These treatments often come with side effects that require optimal management.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Oncology
Shulan Xie, Xuanwei Wang, Shuyuan Gan, Xiaodong Tang, Xianhui Kang, Shengmei Zhu
Summary: TRAP1, a member of the Hsp90 chaperone family, plays a crucial role in tumor progression by regulating metabolism and apoptotic pathways. It is an important therapeutic target for cancer, and combining TRAP1 inhibitors with chemotherapy may represent a new treatment strategy. This review discusses the molecular mechanisms of TRAP1 in tumor progression and recent advances in selective, targeted TRAP1 and Hsp90 inhibitors.
FRONTIERS IN ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Chao Wang, Yujing Zhang, Tingting Zhang, Jiazhen Xu, Saisai Yan, Bing Liang, Dongming Xing
Summary: Overexpression of EGFR has been linked to various cancers, and drug resistance caused by EGFR mutations is a significant challenge. EGFR dual-target inhibitors show promise in overcoming drug resistance and have higher efficacy compared to single-target inhibitors.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Oncology
Zhaodan Xin, Liting You, Feifei Na, Jin Li, Min Chen, Jiajia Song, Ling Bai, Jie Chen, Juan Zhou, Binwu Ying
Summary: In this study, the researchers identified several immunogenetic variants associated with immune-related adverse events (irAEs) and irAEs-free survival in patients treated with PD-1/PD-L1 inhibitors, which could serve as potential predictive biomarkers.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Immunology
Joao Gorgulho, Christoph Roderburg, Fabian Beier, Carsten Bokemeyer, Tim H. Bruemmendorf, Tom Luedde, Sven H. Loosen
Summary: CD3+HLADR+ cells in peripheral blood can serve as a biomarker for immune checkpoint inhibitor (ICI) therapy, and their association with specific gut microbiome species can indicate individual treatment outcomes.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Clara Martori, Lidia Sanchez-Moral, Tony Paul, Juan Carlos Pardo, Albert Font, Vicenc Ruiz de Porras, Maria-Rosa Sarrias
Summary: Immunotherapy has limited efficacy in patients with metastatic prostate cancer due to the immunosuppressive tumor microenvironment, which includes tumor-associated macrophages. Targeting macrophages could offer a promising strategy to reduce tumor progression and enhance immunotherapy efficacy in the treatment of metastatic prostate cancer.
Article
Immunology
Gemma Leon, Yasmina E. Hernandez Santana, Naoise Irwin, Eirini Giannoudaki, Sadhbh O'Neill, Ilona Csizmadia, Martina Gogarty, Tae J. Lee, Darren Ruane, Aideen Long, Padraic G. Fallon, Seamus Hussey, Patrick T. Walsh
Summary: IL-36 cytokines play a crucial role in intestinal inflammation and may be involved in the pathogenesis of inflammatory bowel diseases. The study found that IL-36 alpha is specifically elevated in the serum of newly diagnosed pediatric IBD patients, while IL-36 beta and IL-36 gamma are not. T cells were identified as the primary mediators of IL-36 responses in the inflamed gut.
MUCOSAL IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Stephen F. Madden, Mattia Cremona, Angela M. Farrelly, Weng Hei Low, Jean McBryan
Summary: This study presents a novel proteomic timecourse dataset, profiling potential drug targets in tamoxifen-treated MCF7 cells. It identifies a biphasic response to tamoxifen and identifies key molecular mechanisms during the growth-impeded phase.
CANCER GENE THERAPY
(2023)
Article
Oncology
Cha Len Lee, Mattia Cremona, Angela Farrelly, Julie A. Workman, Sean Kennedy, Razia Aslam, Aoife Carr, Stephen Madden, Brian O'Neill, Bryan T. Hennessy, Sinead Toomey
Summary: Background studies have shown the effectiveness of Palbociclib, Gedatolisib, and PD0325901 in treating colorectal cancer (CRC), but single agent therapies often face resistance. This study compares the anti-proliferative effects of combinations of Gedatolisib and Palbociclib, and Gedatolisib and PD0325901 in different CRC cell lines, and examines their impact on signaling pathway proteins. The results demonstrate that the combination of Palbociclib and Gedatolisib is superior and has synergistic anti-proliferative effects in both wild-type and mutated CRC cell lines. The phosphorylation of S6rp may serve as a promising biomarker for the responsiveness to this combination therapy.
CANCER BIOLOGY & THERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Stephen William Sheridan, Friedrich Wetterling, Jeffrey Moore Testani, Barry A. A. Borlaug, Marat Fudim, Kevin Damman, Alastair Gray, Peter Gaines, Martin Poloczek, Stephen Madden, James Tucker, Teresa Buxo, Robert Gaul, Louise Corcoran, Fiachra Sweeney, Daniel Burkhoff
Summary: This study aimed to investigate the safety and dynamic response of a novel passive inferior vena cava (IVC) sensor in a chronic ovine model. The results showed that the sensor can measure IVC area remotely in real-time and has higher sensitivity than filling pressures, making it an effective tool for detecting congestion.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Nutrition & Dietetics
Ian A. J. Darragh, Lorraine O'Driscoll, Brendan Egan
Summary: This study examined within-subject variability in the circulating metabolome under controlled conditions and investigated the association between divergent exercise training backgrounds and alterations in the circulating metabolome in resting samples. The results showed that the reliability of resting plasma metabolite concentrations varied at the level of individual metabolites, and a history of exercise training was associated with alterations in the abundance of certain metabolites.
INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM
(2023)
Letter
Dermatology
Claire Drumm, Ciara Griffin, Susan Van Baarsel, Claire Quigley, Stephen Madden, Jarushka Naidoo, Karen Eustace
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Multidisciplinary Sciences
Sandra Roche, Patricia Gaule, Deirdre Winrow, Nupur Mukherjee, Fiona O'Neill, Neil T. T. Conlon, Justine Meiller, Denis M. M. Collins, Alexandra Canonici, Mohammed Ibrahim Fawsi, Alejandra Estepa-Fernandez, Stephen F. F. Madden, John Crown, Norma O'Donovan, Alex J. J. Eustace
Summary: Triple Negative Breast Cancer (TNBC), a subtype of breast cancer, has fewer successful therapeutic therapies than other types of breast cancer. Insulin-like growth factor receptor 1 (IGF1R) and the Insulin receptor (IR) are associated with poor outcomes in TNBC. However, inhibiting both IR/IGF1R is not an effective therapeutic approach to treat TNBC.
Article
Pharmacology & Pharmacy
Anindya Mukhopadhya, Dimitrios Tsiapalis, Niamh McNamee, Brian Talbot, Lorraine O'Driscoll
Summary: This study compared the suitability of MSC EVs and milk EVs as drug delivery vehicles. Milk EVs had significantly higher yields compared to MSC EVs. Electroporation was found to be the most effective method for loading the anti-cancer drug Dox into EVs. Additionally, sonication was observed to have detrimental effects on EVs.
Article
Oncology
Nicola Gaynor, Alfonso Blanco, Stephen F. Madden, Barry Moran, Jean M. Fletcher, Damien Kaukonen, Javier Sanchez Ramirez, Alex J. Eustace, Martina S. J. McDermott, Alexandra Canonici, Sinead Toomey, Ausra Teiserskiene, Bryan T. Hennessy, Norma O'Donovan, John Crown, Denis M. Collins
Summary: This study investigated the alterations in phenotype, genotype, and cytotoxic capacity of circulating immune cells in patients with HER2+ breast cancer after neo-adjuvant treatment. The results showed changes in cytotoxicity and immune cell populations after treatment, and suggested that Pembrolizumab may be a potential biomarker of treatment response in ex vivo ADCC assays.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Ioannis Ntafoulis, Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein, Romain Tching Chi Yen, Rutger K. Balvers, Yunlei Li, Andrew P. Stubbs, Trisha V. Kers, Johan M. Kros, Sean E. Lawler, Laurens V. Beerepoot, Andreas Kremer, Ahmed Idbaih, Maite Verreault, Annette T. Byrne, Alice C. O'Farrell, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Martin J. van den Bent, Clemens M. F. Dirven, Sieger Leenstra, Martine L. M. Lamfers
Summary: This study found that patient-derived glioma stem-like cells (GSCs) retain patient-unique gene expressions despite the loss of their natural environment. Drug screening using GSCs predicted patient response to temozolomide (TMZ) more specifically than the MGMT status alone. Transcriptome analysis identified potential biomarkers for TMZ sensitivity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Neurosciences
Ian A. J. Darragh, Niamh McNamee, Roisin Daly, Sarai Martinez Pacheco, Lorraine O'Driscoll, Brendan Egan
Summary: This study investigated whether individuals with different exercise training histories had varied abundances of small extracellular vesicles (EVs) in resting samples. The results suggest that the abundance and metabolomic profile of small EVs derived from men with divergent exercise training histories are similar to those in resting blood samples.
JOURNAL OF PHYSIOLOGY-LONDON
(2023)
Article
Oncology
Nicola Cosgrove, Alex J. Eustace, Peter O'Donovan, Stephen F. Madden, Bruce Moran, John Crown, Brian Moulton, Patrick G. Morris, Liam Grogan, Oscar Breathnach, Colm Power, Michael Allen, Janice M. Walshe, Arnold D. Hill, Anna Blumel, Darren O'Connor, Sudipto Das, Malgorzata Milewska, Joanna Fay, Elaine Kay, Sinead Toomey, Bryan T. Hennessy, Simon J. Furney
Summary: This study suggests that age, estrogen receptor status, and level of immune cell infiltration may play important roles in predicting the response to neoadjuvant therapy in HER2-positive breast cancer. Clonal evolution analysis reveals the presence of therapy resistant subclones. APOBEC-associated mutagenesis may mediate the immunogenic phenotype in HER2-negative/HER2-positive subtype.
Meeting Abstract
Oncology
Dalal AlSultan, Alex J. Eustace, Stephen F. Madden, John Crown
Article
Cell & Tissue Engineering
Dimitrios Tsiapalis, Achilleas Floudas, Tobias Tertel, Verena Boerger, Bernd Giebel, Douglas J. Veale, Ursula Fearon, Lorraine O'Driscoll
Summary: This study investigated the effect of human mesenchymal/stromal stem cells and their extracellular vesicles (EVs) on CD4+ T cells from rheumatoid arthritis (RA) patients. The researchers found that EVs from IFN-beta-primed MSCs had a stronger immune-regulatory effect on RA CD4+ T cells compared to MSCs or EVs from naive MSCs. In addition, EVs from IFN-beta-primed MSCs effectively inhibited RA FLS migration and downregulated RA FLS surface markers. These findings suggest that EVs from IFN-beta-primed MSCs could be a potential therapy for RA.
STEM CELLS TRANSLATIONAL MEDICINE
(2023)
Article
Physiology
Ian A. J. Darragh, Sarai Martinez-Pacheco, Lorraine O'Driscoll, Brendan Egan
Summary: This study investigated the effects of plasma from different training groups on BT-549 breast cancer cells. The results showed that supplementing media with plasma from trained athletes did not impact the proliferation, migration, invasion, and anoikis resistance of the cells.
EXPERIMENTAL PHYSIOLOGY
(2023)